Workflow
Countdown to Abbott (ABT) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
AbbottAbbott(US:ABT) ZACKS·2025-07-14 14:16

Core Viewpoint - Abbott (ABT) is expected to report quarterly earnings of $1.25 per share, reflecting a 9.7% increase year-over-year, with revenues projected at $11.07 billion, a 6.7% increase compared to the previous year [1]. Earnings Estimates - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong correlation between earnings estimate revisions and short-term stock performance [2]. Key Metrics Forecast - Analysts predict 'Net sales- Nutrition' to reach $2.24 billion, indicating a 4.3% increase from the prior year [4]. - The consensus for 'Net sales- Medical Devices- Diabetes Care' is $1.94 billion, reflecting a 17.5% year-over-year change [4]. - 'Net sales- Diagnostics' is expected to reach $2.22 billion, showing a 1% increase from the previous year [4]. - 'Net sales- Established Pharmaceuticals' is forecasted at $1.37 billion, a 6.1% increase year-over-year [5]. - 'Net sales- Diagnostics- U.S.' is estimated at $832.19 million, indicating a 2.5% increase [5]. - 'Net sales- Diagnostics- International' is projected to be $1.38 billion, reflecting a 0.1% increase [5]. - 'Net sales- Nutrition- International' is expected to reach $1.26 billion, a 3.5% year-over-year change [6]. - 'Net sales- Nutrition- U.S.' is forecasted at $985.20 million, indicating a 5.6% increase [6]. - 'Net sales- Medical Devices- Neuromodulation- International' is estimated at $53.47 million, reflecting a 4.8% increase [7]. - 'Net sales- Medical Devices- Rhythm Management- U.S.' is projected at $312.05 million, indicating a 6.9% increase [7]. - 'Net sales- Medical Devices- Rhythm Management- International' is expected to reach $334.64 million, reflecting a 6.2% year-over-year change [8]. - 'Net sales- Medical Devices- Structural Heart- U.S.' is forecasted at $304.28 million, indicating a 17.9% increase [8]. Stock Performance - Abbott shares have decreased by 2.7% over the past month, contrasting with the Zacks S&P 500 composite's 4% increase, but the company holds a Zacks Rank 2 (Buy), suggesting expected outperformance in the near term [8].